Development and commercialisation of chemotherapeutic reformulation, Deflexifol.
Key Highlights
Deflexifol is a reformulation of chemotherapies designed to reduce their toxicity and improve their efficacy.
Promising pre-clinical trials completed.
Second bridging trial to be conducted.
Next proposal for confirmatory clinical study.
Followed by drug registration.
Registered patents.
Exit strategy: out license to large pharm company.
Multi-disciplinary research team.
Personnel with drug commercialisation experience.